Prosensa »

  • Stock market » Prosensa plummets on trial data
    September 21, 2013, 06:39 GMT

    Shares of Prosensa (NASDAQ:RNA) traded sharply lower on Friday morning following some startling news surrounding the company’s muscular dystrophy drug. Over the last year the biotechnology sector has performed exceptionally well. Some of the largest names within the sector have run to the upside by more than 100%. Exuberance within the sector has caused a